Effectiveness of alendronate as an adjunct to scaling and root planing in the treatment of periodontitis: a meta-analysis of randomized controlled clinical trials
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Alendronate has been proposed as a local and systemic drug treatment used as an adjunct to scaling and root planing (SRP) for the treatment of periodontitis. However, its effectiveness has yet to be conclusively established. The purpose of the present meta-analysis was to assess the effectiveness of SRP with alendronate on periodontitis compared to SRP alone. Methods: Five electronic databases were used by 2 independent reviewers to identify relevant articles from the earliest records up to September 2016. Randomized controlled trials (RCTs) comparing SRP with alendronate to SRP with placebo in the treatment of periodontitis were included. The outcome measures were changes in bone defect fill, probing depth (PD), and clinical attachment level (CAL) from baseline to 6 months. A fixed-effect or random-effect model was used to pool the extracted data, as appropriate. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Cochrane χ2 and I2 tests. Results: After the selection process, 8 articles were included in the meta-analysis. Compared with SRP alone, the adjunctive mean benefits of locally delivered alendronate were 38.25% for bone defect fill increase (95% CI=33.05%–43.45%; P<0.001; I2=94.0%), 2.29 mm for PD reduction (95% CI=2.07–2.52 mm; P<0.001; I2=0.0%) and 1.92 mm for CAL gain (95% CI=1.55–2.30 mm; P<0.001; I2=66.0%). In addition, systemically administered alendronate with SRP significantly reduced PD by 0.36 mm (95% CI=0.18–0.55 mm; P<0.001; I2=0.0%) and increased CAL by 0.39 mm (95% CI=0.11–0.68 mm; P=0.006; I2=6.0%). Conclusions: The collective evidence regarding the adjunctive use of alendronate locally and systemically with SRP indicates that the combined treatment can improve the efficacy of non-surgical periodontal therapy on increasing CAL and bone defect fill and reducing PD. However, precautions must be exercised in interpreting these results, and multicenter studies evaluating this specific application should be carried out.
Abstract
Purpose: Alendronate has been proposed as a local and systemic drug treatment used as an adjunct to scaling and root planing (SRP) for the treatment of periodontitis. However, its effectiveness has yet to be conclusively established. The purpose of the present meta-analysis was to assess the effectiveness of SRP with alendronate on periodontitis compared to SRP alone. Methods: Five electronic databases were used by 2 independent reviewers to identify relevant articles from the earliest records up to September 2016. Randomized controlled trials (RCTs) comparing SRP with alendronate to SRP with placebo in the treatment of periodontitis were included. The outcome measures were changes in bone defect fill, probing depth (PD), and clinical attachment level (CAL) from baseline to 6 months. A fixed-effect or random-effect model was used to pool the extracted data, as appropriate. Mean differences (MDs) with 95% confidence intervals (CIs) were calculated. Heterogeneity was assessed using the Cochrane χ2 and I2 tests. Results: After the selection process, 8 articles were included in the meta-analysis. Compared with SRP alone, the adjunctive mean benefits of locally delivered alendronate were 38.25% for bone defect fill increase (95% CI=33.05%–43.45%; P<0.001; I2=94.0%), 2.29 mm for PD reduction (95% CI=2.07–2.52 mm; P<0.001; I2=0.0%) and 1.92 mm for CAL gain (95% CI=1.55–2.30 mm; P<0.001; I2=66.0%). In addition, systemically administered alendronate with SRP significantly reduced PD by 0.36 mm (95% CI=0.18–0.55 mm; P<0.001; I2=0.0%) and increased CAL by 0.39 mm (95% CI=0.11–0.68 mm; P=0.006; I2=6.0%). Conclusions: The collective evidence regarding the adjunctive use of alendronate locally and systemically with SRP indicates that the combined treatment can improve the efficacy of non-surgical periodontal therapy on increasing CAL and bone defect fill and reducing PD. However, precautions must be exercised in interpreting these results, and multicenter studies evaluating this specific application should be carried out.
참고문헌 (31)
- "Periodontal diseases: pathogenesis and microbial factors", J Am Dent Assoc, 129(Suppl), pp.58S~62S (1998)
- Armitage GC, "The biology, prevention, diagnosis and treatment of periodontal diseases: scientific advances in the United States", J Am Dent Assoc, 140(Suppl 1), pp.36S~43S (2009)
- Lindhe J, "The effect of plaque control and surgical pocket elimination on the establishment and maintenance of periodontal health. A longitudinal study of periodontal therapy in cases of advanced disease", J Clin Periodontol, 2, pp.67~79 (1975)
- Hill RW, "Four types of periodontal treatment compared over two years", J Periodontol, 52, pp.655~662 (1981)
- Ramfjord SP, "Four modalities of periodontal treatment compared over five years", J Periodontal Res, 22, pp.222~223 (1987)
- Salvi GE, "Host response modulation in the management of periodontal diseases", J Clin Periodontol, 32(Suppl 6), pp.108~129 (2005)
- Offenbacher S, "Periodontal diseases: pathogenesis", Ann Periodontol, 1, pp.821~878 (1996)
- Graves D, "Cytokines that promote periodontal tissue destruction", J Periodontol, 79, pp.1585~1591 (2008)
- Ciancio SG, "Systemic medications : clinical significance in periodontics", J Clin Periodontol, 29(Suppl 2), pp.17~21 (2002)
- Reszka AA, "Bisphosphonate mechanism of action", Curr Rheumatol Rep, 5, pp.65~74 (2003)
- Rogers MJ, "Cellular and molecular mechanisms of action of bisphosphonates", Cancer, 88, pp.2961~2978 (2000)
- Binderman I, "Effectiveness of local delivery of alendronate in reducing alveolar bone loss following periodontal surgery in rats", J Periodontol, 71, pp.1236~1240 (2000)
- Tenenbaum HC, "Bisphosphonates and periodontics: potential applications for regulation of bone mass in the periodontium and other therapeutic", diagnostic uses, 2002, pp.73, 813~822
- Weinreb M, "Histomorphometrical analysis of the effects of the bisphosphonate alendronate on bone loss caused by experimental periodontitis in monkeys", J Periodontal Res, 29, pp.35~40 (1994)
- Hu JH, "Effects of short-term alendronate treatment on the three-dimensional microstructural, physical, and mechanical properties of dog trabecular bone", Bone, 31, pp.591~597 (2002)
- Veena HR, "Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects", J Indian Soc Periodontol, 14, pp.40~45 (2010)
- Kruszewska H, "Search of antimicrobial activity of selected non-antibiotic drugs", Acta Pol Pharm, 59, pp.436~439 (2002)
- Liberati A, "The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration", J Clin Epidemiol, 62, pp.e1~34 (2009)
- Moher D, "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement", J Clin Epidemiol, 62, pp.1006~1012 (2009)
- Higgins JP, "Cochrane handbook for systematic reviews of interventions version 5.1.0" (2011), The Cochrane Collaboration
- Pradeep AR, "1% alendronate gel as local drug delivery in the treatment of Class II furcation defects: a randomized controlled clinical trial", J Periodontol, 84, pp.307~315 (2013)
- Sharma A, "Clinical efficacy of 1% alendronate gel as a local drug delivery system in the treatment of chronic periodontitis: a randomized, controlled clinical trial", J Periodontol, 83, pp.11~18 (2012)
- Sharma A, "Clinical efficacy of 1% alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial", J Periodontol, 83, pp.19~26 (2012)
- Pradeep AR, "Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial", J Periodontol, 83, pp.1322~1328 (2012)
- Pradeep AR, "Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial", J Investig Clin Dent (2016)
- Lane N, "Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study", J Periodontol, 76, pp.1113~1122 (2005)
- Rocha M, "Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial", J Periodontol, 72, pp.204~209 (2001)
- Rocha ML, "Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial", J Periodontol, 75, pp.1579~1585 (2004)
- Durie BG, "Osteonecrosis of the jaw and bisphosphonates", N Engl J Med, 353, pp.99~102 (2005)
- De Almeida J, "Adjuvant therapy with sodium alendronate for the treatment of experimental periodontitis in rats", J Periodontol, 86, pp.1166~1175 (2015)
- Menezes AM, "Effect of sodium alendronate on alveolar bone resorption in experimental periodontitis in rats", J Periodontol, 76, pp.1901~1909 (2005)